[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621831":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":25,"responsibleParty":32,"collaborators":25,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":25,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":25,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":62,"whyStopped":25,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":25},{"fullName":5,"class":6},"Carnegie Mellon University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stimulation of Occipital Cortex","SHAM_COMPARATOR","Transcranial Electrical Stimulation will be delivered to the occipital cortex (mapped using the 10 20 EEG system) at a similar current\u002Fpain level as the active stimulation trial.",[13],"Device: Transcranial Electrical Stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Motor Cortex Stimulation","EXPERIMENTAL","Transcranial electrical stimulation will be delivered to the primary motor cortex (mapped using the 10-20 EEG system) and current will be injected such that there are evoked motor potentials in the distal extremities.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Transcranial Electrical Stimulation","SharpFocus transcranial electrical stimulation (TES) uses a multichannel stimulator connected to a scalp electrode to deliver precisely timed, intensity-modulated electrical pulses. By varying the timing, amplitude, and location of these pulses, the system achieves focal stimulation of targeted cortical regions.\n\nInvestigators will use Digitimer DS8R and\u002For Digitimer DS5 current stimulators to apply all current stimuli. These stimulators are CE certified and are intended for use in human research applications. The stimulator safely delivers brief duration (50-2000µs) current pulses for transcranial electrical stimulation and activation of nerves and muscles via surface electrodes. The current output of the DS8R is adjustable over the range 0mA to 1000mA, with a compliance voltage of up to 400V and an energy limit of 300mJ.",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Pulkit Grover, PhD","CONTACT","412-268-3644","pgrover@andrew.cmu.edu",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Pulkit Grover","Professor","100621831","transcranial-electrical-stimulation-for-noninvasive-study-of-menopausalperimenopausal-symptoms-100621831",false,"NCT07375732","Transcranial Electrical Stimulation for Noninvasive Study of Menopausal\u002FPerimenopausal Symptoms","Inclusion Criteria:\n\n* Age between 40 and 60 years\n* Participants falling under stages -2 to +2 in the Stages of Reproductive Aging Workshop (STRAW +10) as defined below:\n* Early menopause transition (Stage -2): Increased variability in menstrual cycle defined as persistent difference of 7 days or more in the length of consecutive cycles. Persistence is defined as recurrence within 10 cycles of the first variable cycle.\n* Late menopause transition (Stage -1): Occurrence of amenorrhea of 60 days or longer.\n* Final Menstrual Period (Stage 0): Have undergone 12 consecutive months without a menstrual period, not due to other medical causes.\n* Early Postmenopause (Stage +1): 5-8 years after final menstrual period.\n* Late Postmenopause (Stage +2): \\>8 years after final menstrual period.\n* Participants having frequent hot flashes (at least once a day).\n\nExclusion Criteria:\n\n* Disorders that may mask or coincide with menopause and peri-menopause, such as: Primary Ovarian Insufficiency, Thyroid disease (Hyper\u002Fhypothyroidism), Hyperprolactinemia, Cushing's syndrome, Endometrial\u002FOvarian Cancer, Polycystic Ovary Syndrome (PCOS), Functional hypothalamic amenorrhea\n* Concurrent drugs:\n* GnRH agonist\u002Fantagonist\n* Tamoxifen\u002Faromatase inhibitors\n* Other conditions: Recent hematoma (\\\u003C48 hours), History of hemorrhagic disorders (any platelet disorder (ITP, TTP, HUS, Glanzmann thrombasthenia), Hemophilia A\u002FB, history of arterial insufficiency, any prior history of malignancy, current pregnancy, a lifetime history of severe, uncontrolled mood disorders (anxiety, depression, bipolar), psychotic disorders, other neural disorders, or heart disease, any condition that makes them unable to perform tasks outlined in experiment, tattoos on sensory testing sites.","FEMALE","40 Years","60 Years",{"count":46,"type":47},50,"ESTIMATED","INTERVENTIONAL",[50],"NA","Participants are being invited to a research study. This research aims to assess the tolerability of transcranial electrical stimulation of the brain, and explore the response of TES on menopausal\u002Fperimenopausal symptoms including hot flashes effects, depression\u002Fanxiety, memory-problems, and muscular problems. This study will assess what types of electrical brain stimulation affect different menopausal related symptoms. This study will help guide the development of electrical stimulation to be used for improving women's health during menopause transition.",[53,54,55,56],"Menopausal Depression","Menopause Hot Flashes","Menopause","Menopause Related Conditions",[58,22,59,60,61],"Noninvasive Neuromodulation","Depression","Vasomotor Symptoms","Hot Flashes","NOT_YET_RECRUITING","2026-01-26",{"date":65,"type":66},"2026-01-29","ACTUAL",{"date":68,"type":47},"2026-02",{"date":70,"type":47},"2027-04",{"name":5,"class":6}]